Hongsheng Lu
-
- Cancer-related molecular mechanisms research 8
-
- Cancer Immunotherapy and Biomarkers 4
- Peptidase Inhibition and Analysis 4
-
- RNA modifications and cancer 6
- Circular RNAs in diseases 4
-
- Renal cell carcinoma treatment 4
- Ferroptosis and cancer prognosis 4
-
- Histiocytic Disorders and Treatments 3
- Journals
- SHILAP Revista de lepidopterología (2 papers)PLoS ONE (1 paper)Scientific Reports (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Hongsheng Lu
64 papers receiving 681 citations
Peers
Comparison fields: 5 of 112
- Cancer Research 137
- Oncology 130
- Molecular Biology 277
- Immunology 77
- Pulmonary and Respiratory Medicine 111
Countries citing papers authored by Hongsheng Lu
This map shows the geographic impact of Hongsheng Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongsheng Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongsheng Lu more than expected).
Fields of papers citing papers by Hongsheng Lu
This network shows the impact of papers produced by Hongsheng Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongsheng Lu. The network helps show where Hongsheng Lu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hongsheng Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 4 | |
| 3 | 2023 | 15 | |
| 4 | 2023 | 39 | |
| 5 | 2023 | 11 | |
| 6 | 2023 | 32 | |
| 7 | 2023 | 6 | |
| 8 | 2022 | 5 | |
| 9 | 2022 | 3 | |
| 10 | 2022 | 9 | |
| 11 | 2022 | 2 | |
| 12 | 2022 | 14 | |
| 13 | 2022 | 24 | |
| 14 | 2021 | 8 | |
| 15 | 2021 | 9 | |
| 16 | 2020 | 6 | |
| 17 | 2014 | 24 | |
| 18 | 2014 | 35 | |
| 19 | 2012 | 25 | |
| 20 | 2010 | 7 |
About Hongsheng Lu
Hongsheng Lu is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 68 papers that have together received 696 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (8 papers), RNA modifications and cancer (6 papers), Renal cell carcinoma treatment (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Ferroptosis and cancer prognosis (4 papers), Peptidase Inhibition and Analysis (4 papers), Circular RNAs in diseases (4 papers) and Histiocytic Disorders and Treatments (3 papers). The work is most often cited by research in Cancer Research (137 citations), Oncology (130 citations) and Molecular Biology (277 citations). Hongsheng Lu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Meifu Gan, Hui Zhang, Qi Chen, Lili Chen, Wenwu Zhong, Shiqing Zhang, Shijie Shen, Siling Wang, Yanyun Ruan and Tao Zhou. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.